More anti-cancer drugs are set to be introduced in the Chinese market as leading pharmaceutical companies join the 2nd China International Import Expo.
Several enterprises, including Pfizer Biopharmaceuticals Group, Roche Pharmaceuticals and Merck Sharp & Dohme, introduced the drugs yesterday that they will exhibit at the November expo in Shanghai
Pfizer Inc. is an American multinational pharmaceutical corporation based in New York City with its research headquarters in Groton, Connecticut. It is one of the world’s largest pharmaceutical companies, ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. It has been in the Chinese market for 30 years and has invested over US$1.5 billion in China.
Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline on December 19, 2019.
Country lead of Pfizer China Biopharma, Wu Kun revealed that the company will introduce Ibrance, something that advanced-stage breast cancer patients can take. Four advanced production facilities and two research and development centers are being set up in order to introduce over 60 new drugs in the market.
Roche Pharmaceuticals China is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics based in Basel. It stands out in the field pharmaceuticals for cancer treatment, against virus diseases and for treatment of metabolic diseases, claiming the world’s largest spender in pharmaceutical R&D spot.
Roche Pharmaceuticals China is the first transnational pharmaceutical company to build a fully owned R&D center in Shanghai. It further stated that two of its anti-cancer drug has been submitted for price negotiations in China and is currently waiting for approval to be included in the national reimbursement drug list to lessen the financial burden brought upon the patients.
Come the expo, their new products and the latest technology in the fields of breast cancer, influenza and cancer immunotherapy will be displayed in a 700-square-meter booth.
On the other hand, China was perceived by Johnson & Johnson to be an essential base to promote R&D because a lot of pharmaceutical industry innovations came from China. MSD will take an 800sqm booth that’ll showcase showcase drugs, vaccines and animal health products and services that will support the country’s “Healthy China 2030″ campaign.